Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia

Koji Nagafuji, Toshihiro Miyamoto, Tetsuya Eto, Ryosuke Ogawa, Hirokazu Okumura, Ken Takase, Noriaki Kawano, Yasuhiko Miyazaki, Tomoaki Fujisaki, Atsushi Wake, Yuju Ohno, Toshiro Kurokawa, Tomohiko Kamimura, Yasushi Takamatsu, Shouhei Yokota, Koichi Akashi

研究成果: ジャーナルへの寄稿記事

抄録

Objective: We investigated whether minimal residual disease (MRD) status in adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) is useful for decision on clinical indications for allogeneic hematopoietic stem cell transplantation (HSCT). Methods: We prospectively monitored MRD after induction and consolidation therapy in adult patients with Ph-negative ALL. Results: Among 103 adult ALL patients enrolled, 59 were Ph-negative, and MRD status was assessed in 51 patients. The probability of 3-year overall survival (OS) and disease-free survival (DFS) was 69% (95%CI 54-80) and 50% (95%CI 36-63), respectively. Patients who were MRD-negative after induction therapy (n = 15) had a significantly better 3-year DFS compared with those who were MRD-positive (n = 30; 73% vs 41%, P = 0.018). Patients who were MRD-positive after induction but became MRD-negative after consolidation chemotherapy C in the first course (n = 11) showed a significantly worse 3-year DFS compared with patients who were MRD-negative after induction chemotherapy A in the first course (45% vs 73%, P = 0.025). Conclusions: These results indicate that DFS of about 70% can be expected in MRD-negative patients after induction therapy, and the patients did not benefit from HSCT in 1CR. This study was registered with the UMIN Clinical Trials Registry (UMIN-CTR), number UMIN000001519.

元の言語英語
ページ(範囲)164-171
ページ数8
ジャーナルEuropean Journal of Haematology
103
発行部数3
DOI
出版物ステータス出版済み - 1 1 2019

Fingerprint

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Hematopoietic Stem Cell Transplantation
Consolidation Chemotherapy
Philadelphia Chromosome
Induction Chemotherapy
Registries
Therapeutics
Clinical Trials
Survival

All Science Journal Classification (ASJC) codes

  • Hematology

これを引用

Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia. / Nagafuji, Koji; Miyamoto, Toshihiro; Eto, Tetsuya; Ogawa, Ryosuke; Okumura, Hirokazu; Takase, Ken; Kawano, Noriaki; Miyazaki, Yasuhiko; Fujisaki, Tomoaki; Wake, Atsushi; Ohno, Yuju; Kurokawa, Toshiro; Kamimura, Tomohiko; Takamatsu, Yasushi; Yokota, Shouhei; Akashi, Koichi.

:: European Journal of Haematology, 巻 103, 番号 3, 01.01.2019, p. 164-171.

研究成果: ジャーナルへの寄稿記事

Nagafuji, K, Miyamoto, T, Eto, T, Ogawa, R, Okumura, H, Takase, K, Kawano, N, Miyazaki, Y, Fujisaki, T, Wake, A, Ohno, Y, Kurokawa, T, Kamimura, T, Takamatsu, Y, Yokota, S & Akashi, K 2019, 'Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia', European Journal of Haematology, 巻. 103, 番号 3, pp. 164-171. https://doi.org/10.1111/ejh.13268
Nagafuji, Koji ; Miyamoto, Toshihiro ; Eto, Tetsuya ; Ogawa, Ryosuke ; Okumura, Hirokazu ; Takase, Ken ; Kawano, Noriaki ; Miyazaki, Yasuhiko ; Fujisaki, Tomoaki ; Wake, Atsushi ; Ohno, Yuju ; Kurokawa, Toshiro ; Kamimura, Tomohiko ; Takamatsu, Yasushi ; Yokota, Shouhei ; Akashi, Koichi. / Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia. :: European Journal of Haematology. 2019 ; 巻 103, 番号 3. pp. 164-171.
@article{15c48f4a354a47a39aa6302f7990572e,
title = "Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia",
abstract = "Objective: We investigated whether minimal residual disease (MRD) status in adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) is useful for decision on clinical indications for allogeneic hematopoietic stem cell transplantation (HSCT). Methods: We prospectively monitored MRD after induction and consolidation therapy in adult patients with Ph-negative ALL. Results: Among 103 adult ALL patients enrolled, 59 were Ph-negative, and MRD status was assessed in 51 patients. The probability of 3-year overall survival (OS) and disease-free survival (DFS) was 69{\%} (95{\%}CI 54-80) and 50{\%} (95{\%}CI 36-63), respectively. Patients who were MRD-negative after induction therapy (n = 15) had a significantly better 3-year DFS compared with those who were MRD-positive (n = 30; 73{\%} vs 41{\%}, P = 0.018). Patients who were MRD-positive after induction but became MRD-negative after consolidation chemotherapy C in the first course (n = 11) showed a significantly worse 3-year DFS compared with patients who were MRD-negative after induction chemotherapy A in the first course (45{\%} vs 73{\%}, P = 0.025). Conclusions: These results indicate that DFS of about 70{\%} can be expected in MRD-negative patients after induction therapy, and the patients did not benefit from HSCT in 1CR. This study was registered with the UMIN Clinical Trials Registry (UMIN-CTR), number UMIN000001519.",
author = "Koji Nagafuji and Toshihiro Miyamoto and Tetsuya Eto and Ryosuke Ogawa and Hirokazu Okumura and Ken Takase and Noriaki Kawano and Yasuhiko Miyazaki and Tomoaki Fujisaki and Atsushi Wake and Yuju Ohno and Toshiro Kurokawa and Tomohiko Kamimura and Yasushi Takamatsu and Shouhei Yokota and Koichi Akashi",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ejh.13268",
language = "English",
volume = "103",
pages = "164--171",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia

AU - Nagafuji, Koji

AU - Miyamoto, Toshihiro

AU - Eto, Tetsuya

AU - Ogawa, Ryosuke

AU - Okumura, Hirokazu

AU - Takase, Ken

AU - Kawano, Noriaki

AU - Miyazaki, Yasuhiko

AU - Fujisaki, Tomoaki

AU - Wake, Atsushi

AU - Ohno, Yuju

AU - Kurokawa, Toshiro

AU - Kamimura, Tomohiko

AU - Takamatsu, Yasushi

AU - Yokota, Shouhei

AU - Akashi, Koichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: We investigated whether minimal residual disease (MRD) status in adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) is useful for decision on clinical indications for allogeneic hematopoietic stem cell transplantation (HSCT). Methods: We prospectively monitored MRD after induction and consolidation therapy in adult patients with Ph-negative ALL. Results: Among 103 adult ALL patients enrolled, 59 were Ph-negative, and MRD status was assessed in 51 patients. The probability of 3-year overall survival (OS) and disease-free survival (DFS) was 69% (95%CI 54-80) and 50% (95%CI 36-63), respectively. Patients who were MRD-negative after induction therapy (n = 15) had a significantly better 3-year DFS compared with those who were MRD-positive (n = 30; 73% vs 41%, P = 0.018). Patients who were MRD-positive after induction but became MRD-negative after consolidation chemotherapy C in the first course (n = 11) showed a significantly worse 3-year DFS compared with patients who were MRD-negative after induction chemotherapy A in the first course (45% vs 73%, P = 0.025). Conclusions: These results indicate that DFS of about 70% can be expected in MRD-negative patients after induction therapy, and the patients did not benefit from HSCT in 1CR. This study was registered with the UMIN Clinical Trials Registry (UMIN-CTR), number UMIN000001519.

AB - Objective: We investigated whether minimal residual disease (MRD) status in adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) is useful for decision on clinical indications for allogeneic hematopoietic stem cell transplantation (HSCT). Methods: We prospectively monitored MRD after induction and consolidation therapy in adult patients with Ph-negative ALL. Results: Among 103 adult ALL patients enrolled, 59 were Ph-negative, and MRD status was assessed in 51 patients. The probability of 3-year overall survival (OS) and disease-free survival (DFS) was 69% (95%CI 54-80) and 50% (95%CI 36-63), respectively. Patients who were MRD-negative after induction therapy (n = 15) had a significantly better 3-year DFS compared with those who were MRD-positive (n = 30; 73% vs 41%, P = 0.018). Patients who were MRD-positive after induction but became MRD-negative after consolidation chemotherapy C in the first course (n = 11) showed a significantly worse 3-year DFS compared with patients who were MRD-negative after induction chemotherapy A in the first course (45% vs 73%, P = 0.025). Conclusions: These results indicate that DFS of about 70% can be expected in MRD-negative patients after induction therapy, and the patients did not benefit from HSCT in 1CR. This study was registered with the UMIN Clinical Trials Registry (UMIN-CTR), number UMIN000001519.

UR - http://www.scopus.com/inward/record.url?scp=85068475328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068475328&partnerID=8YFLogxK

U2 - 10.1111/ejh.13268

DO - 10.1111/ejh.13268

M3 - Article

C2 - 31132205

AN - SCOPUS:85068475328

VL - 103

SP - 164

EP - 171

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 3

ER -